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Abstract
Despite remarkable advances in our understanding of a
genetic basis of cancer, the precise molecular defini-
tion of the phenotypically relevant genetic features
associatedwith human epithelial malignancies remains
a significant and highly relevant challenge. Here we
performed a systematic analysis of the chromosomal
positions of cancer-associated transcripts for prostate,
breast, ovarian, and colon tumors, and identified short
segments of human chromosomes that appear to
represent a common target for transcriptional activa-
tion in major epithelial malignancies in human. These
cancer-associated transcriptomeres correspond well
to the regions of transient transcriptional activity
on chromosomes 1q21–q23 (144–160 Mbp), 12q13
(52–63 Mbp), 17q21 (38–50 Mbp), 17q23–q25 (72–82
Mbp), 19p13 (1–16 Mbp), and Xq28 (132–142 Mbp)
during human cell cycle, suggesting a common epi-
genetic mechanism of transcriptional activation. Con-
sistent with this idea, two of these transcriptomeres
(12q13 and 17q21) seemed to be related to the p53-
regulated transcriptional clusters, and some of the
cancer-associated transcriptomeres appeared to cor-
respond well to the recently identified regions of
increased gene expression on human chromosomes.
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Introduction
During malignant progression, genomic instability leads to
continuously emerging phenotypic diversity, clonal evolu-
tion, and clonal selection, resulting in the remarkable cel-
lular heterogeneity of tumors. The phenotypic diversity of
cancer cells is associated with significant mutation-driven
changes in gene expression, although not all mutations and
differences in gene expression are crucial to the malignant
phenotype. Important goals are to identify mutations and
gene expression changes that are highly relevant and
characteristic of malignant phenotypes and progression
pathways, more than one of which may exist [1]. At least
some of the phenotypically relevant changes in the mRNA
abundance levels characteristic of malignancy are mutation-
driven and associated with the recurrent genetic alterations.
Recent parallel comparisons of the alterations in DNA copy
number and gene expression in human breast cancer cell lines
[2,3] revealed that most differentially expressed genes were
not amplified or deleted, nor did all regions of DNA amplifica-
tions or deletions cause gene expression changes. However,
both groups reported that several genes highly overexpressed
in the multiple human breast cancer cell lines were involved in
recurrent DNA amplifications, suggesting that these genes are
more likely to represent important mediators of the breast
cancer progression. Collectively, these data support the idea
that the systematic analysis of the recurrent transcriptional
aberrations in cancer may be useful in the identification of the
recurrent phenotypically relevant genomic changes.
Completion of the draft sequence of the human genome
allowed identification of the chromosomal positions of human
genes with unprecedented accuracy. Integration of these
mapping data with genome-wide messenger RNA expression
profiles as provided by serial analysis of gene expression for
12 tissue types resulted in generation of the human tran-
scriptome map [4]. The map reveals an apparently nonrandom
pattern of chromosomal distribution of transcriptionally active
regions along human chromosomes reflected in a clustering of
highly expressed genes to specific chromosomal segments.
Therefore, we thought to take advantage of these novel
analytical tools and determine whether a systematic analysis
of the chromosomal positions of the cancer-associated genes
with increased mRNA abundance levels would reveal recur-
rent chromosomal regions of transcriptional activations char-
acteristic of cancer. Global gene expression monitoring in
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cancer cell lines and clinical tumor samples showed that
genes with increased mRNA abundance levels exhibited
largely nonoverlapping cancer type–specific patterns of
expression [5–8], consistent with the concept of multiple
independent pathways of tumor progression [1]. In this paper,
we performed an analysis of chromosomal positions of
cancer-associated transcripts identified in multiple independ-
ent data sets, including oligonucleotide microarray data gen-
erated by the Affymetrix gene expression profiling of human
prostate cancer cell lines (this study) and previously pub-
lishedmicroarray data of clinical samples [5–8]. Surprisingly,
analysis of the chromosomal positions of the cancer-associ-
ated genes revealed several recurrent malignancy-associ-
ated regions of transcriptional activation (MARTAs) common
for human prostate, breast, ovarian, and colon cancers.
Materials and Methods
Cell Culture
Cell lines used in this study are described in Table 1. The
PC3-derived and LNCaP-derived cell lines were developed
by consecutive serial orthotopic implantation, either from
metastases to the lymph node (for the LN series), or
reimplanted from the prostate (Pro series). This procedure
generated cell variants with differing tumorigenicity, fre-
quency, and latency of regional lymph node metastasis
[9]. The LNCaP and PC-3 panels of human prostate carci-
noma cell lines of graded metastatic potential were provided
by Dr. C. Pettaway (M.D. Anderson Cancer Center, Hous-
ton, TX) and described earlier [9]. A third progression
model is represented by the P69 cell line, an SV40 large
T-antigen–immortalized prostate epithelial line, and M12, a
metastatic derivative of P69 [10–12]. The P69 and M12 cell
lines [11–13] were obtained from Dr. S. Plymate and Dr. J.
Ware. Two primary human prostate epithelial and one pri-
mary human prostate stromal cell line were obtained from
Clonetics/BioWhittaker (San Diego, CA ) and grown in com-
plete prostate epithelial and stromal growthmedium provided
by the supplier. Except where noted, other cell lines were
grown in RPMI 1640 supplemented with 10% fetal bovine
serum and gentamicin (Gibco BRL, Gaithersburg, MD) to
70% to 80% confluence and subjected to serum starvation as
described [13,14], or maintained in fresh complete media,
supplemented with 10% FBS.
RNA Extraction
For gene expression analysis, cells were harvested in
lysis buffer 2 hours after the last media change at 70% to
80% confluence, and total RNA or mRNA was extracted
using the RNeasy (Qiagen, Chatsworth, CA) or FastTract
kits (Invitrogen, Carlsbad, CA). Cell lines were not split more
than five times, except where noted.
Table 1. Divergent Evolution During Experimentally Extended Tumor Progression In Vivo in Nude Mice of Human Prostate Carcinoma Cell Lines Derived from
Androgen-Dependent (LNCaP) and Androgen-Independent (PC3) Lineages (See Text for Details and References).
Cell Lines Cycles of
Progression
Site of
Transplantation/Recovery
Orthotopic
Tumorigenicity
Metastatic
Potential
RNA Sources Used in This Study
Normal epithelia 0 None None None In vitro; triplicate samples
PC3 0 None High Intermediate
PC3M 1 Prostate/liver High High
PC3M-LN4 4 Prostate/lymph nodes High Very high In vitro; duplicate samples
PC3M-Pro4 4 Prostate/prostate High Intermediate
LNCaP 0 None Intermediate Low
LNCaP-LN3 3 Prostate/lymph nodes High High In vitro; duplicate samples
LNCaP-Pro5 5 Prostate/prostate High Low
P69 0 None Very low None
M12 3 Subcutaneous/prostate High High
RNA from all conditions was prepared twice from independent experiments to assure reproducibility.
Figure 1. RT-PCR confirmation analysis of the upregulation of two genes
representing Xq28 transcription activation cluster in human prostate carcinoma
cell lines [MAGEA12 (top panel) and MAGEA3 transcripts (bottom panel)].
Standard RT-PCR protocol was used to amplify fragments of corresponding
genes from mRNA of the normal human prostate epithelial cells (PrEc) and
highly metastatic PC3MLN4 and LNCaPLN3 human prostate carcinoma cell
lines. To control PCR amplification efficiency and loading, the experiments
were carried out using coamplification in the same tube with each experimental
gene of a fragment of control gene (SYBL1) that was selected to have a similar
chromosomal location but distinct amplification product size and regulation
pattern. In the control experiments (C), PCR amplification was carried out only
for corresponding control genes. H2O—negative control of PCR amplification;
M—molecular weight markers.
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Affymetrix Arrays
The protocol for mRNA quality control and gene expres-
sion analysis was that recommended by Affymetrix (http://
www.affymetrix.com). In brief, approximately 1 Ag of mRNA
was reverse-transcribed with an oligo(dT) primer that has a
T7 RNA polymerase promoter at the 5V-end. Second strand
synthesis was followed by cRNA production incorporating a
biotinylated base. Hybridization to Affymetrix Hu6800 arrays
representing 7129 transcripts overnight for 16 hours was
followed by washing and labeling using a fluorescently
labeled antibody. The arrays were read and data were
processed using Affymetrix equipment and software [16].
Detailed protocols for data analysis and documentation of
the sensitivity, reproducibility, and other aspects of the
quantitative microarray analysis using Affymetrix technology
have been reported [16]. To determine the quantitative
difference in the mRNA abundance levels between two
samples, in each individual sample for each gene, the
average expression differences were calculated from inten-
sity measurements of perfect match (PM) probes minus
corresponding control probes representing single nucleotide
mismatch (MM) oligonucleotides for each gene-specific set
of 20 PM/MM pairs of oligonucleotides, after discarding the
maximum, minimum, and any outliers beyond 3SD. The
averages of pairwise comparisons for each individual gene
were made between the samples and the corresponding
expression difference calls (see below) were made with
Affymetrix software. Microsoft Access was used for other
Figure 2. Genome-wide representation of distribution of transcription activation clusters within a PC3MLN4/LNCaPLN3 consensus class of 165 genes with
increased mRNA abundance levels. The clustering effect in the experimental data set was calculated as a ratio of the average random clustering distance to the
individual measurements of the experimental clustering distance within a given class of differentially regulated transcripts. Higher ratio due to a shorter
experimental clustering distance was interpreted as more significant clustering effect. The cutoff value for identification of the transcription activation clusters was
set to exceed the expected random density of gene distribution by at least 10-fold. The random distribution of the individual clustering distances (d) was obtained by
performing similar analysis for the random gene set (a total of 105 individual measurements). There were no random pseudo-clusters exceeding the cutoff value
that was set for identification of the transcription activation clusters. Note that for more accurate visual comparisons of the clustering effects within experimental and
random gene sets, (a) and (b) scaled to the different Y-axis values, and (c) and (d) scaled to the same Y-axis value. A similar analysis of a genome-wide distribution
of transcription activation clusters was performed for genes upregulated in ovarian (Figure 1S), breast (Figure 2S), and colon (Figure 3S) cancers as well as genes
activated during human cell cycle (Figures 4S and 5S), dsRNA-induced transcripts (Figure 6S), and p53-regulated genes (Figures 7S). These data are presented in
the supplement.
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aspects of data management and storage. For each gene, a
matrix-based decision concerning the difference in the
mRNA abundance level between two samples was made
by the software and reported as a ‘‘difference call’’ [No
change (NC), Increase (I), Decrease (D), Marginal increase
(MI), and Marginal decrease (MD)], and the corresponding
fold change ratio was calculated. The results of 7 array
experiments are presented in this paper. Forty to 50% of
the surveyed genes were called present by the Affymetrix
software in these experiments. The concordance analysis
of differential gene expression across the data set was
performed using Microsoft Access and Affymetrix MicroDB
software. Three of the normal prostate epithelial (NPE)
microarrays are used as controls and referred to as the
NPE expression profile. Thus, when a gene is required to
show a two-fold or greater change relative to NPE, this
must occur in all three microarrays, for either positive or
negative changes. These stringent criteria exclude genes
for which one of the three microarrays is in error. The
strategy in this study is based on the idea that expression
differences will not be called by chance in the same
direction in multiple arrays (see Statistical Analysis and
Quality Performance Criteria section for statistical justifica-
tion). Each gene in the final list of the 165 differentially
expressed genes was required to be called exclusively as
either concordantly upregulated or downregulated in 12
separate comparisons (2 prostate cancer cell lines  2
experimental serum conditions  3 NPE controls).
Statistical Analysis and Quality Performance Criteria
We used stringent analytical approach to test the
hypothesis that there are common genes with altered
Figure 2. (continued)
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mRNA abundance levels, which appear to be significantly
associated with the prostate cancer phenotype in PC3/
LNCaP model systems of human prostate cancer. The
Affymetrix GeneChip gene expression analysis software
identifies in any given comparison of two chips only genes
that are determined to be expressed at the levels of
difference in the expression values determined to be
statistically significant (P<.05). These transcripts are
Figure 3. Profiles of the chromosomal distribution of human breast cancer –associated transcripts (a), dsRNA-induced genes (b), and cell cycle-activated genes
(c) residing on chromosome 17. A total of 132 estrogen receptor-negative breast cancer–associated transcripts was obtained from Ref. [5] by combining the lists of
genes comprising basal epithelial cell clusters 1 and 2, Erb-B2 overexpression cluster, and a proliferative cluster. A total of 144 ovarian cancer –associated
transcripts was derived from Ref. [6] as a sum of the top 100 biomarker genes, proliferative and tumor clusters. The redundant entries were eliminated from the final
gene lists. A total of 165 prostate cancer–associated transcripts was identified by comparing gene expression profiles of two human prostate carcinoma cell lines
(PC3MLN4 and LNCaPLN3) to the gene expression pattern of cultured normal human prostate epithelial cells using the Affymetrix GeneChip system. A concordant
set of 165 genes upregulated in cancer cell lines was generated utilizing the Affymetrix software for pairwise comparisons of duplicate cancer mRNA samples from
each cell line versus a triplicate normal mRNA samples derived from two different normal prostate epithelial cell lines. Thus, each differentially expressed gene was
required to be called in the same direction in 12 pairwise comparisons. The list of 378 genes comprising the human cell cycle transcriptome was obtained from Ref.
[19]. The list of the dsRNA-induced genes was derived from Ref. [20]. RH mapping data were retrieved using the LocusLink database and utilized to generate the
chromosome-specific map of gene distribution. One unit value on the Y-axis corresponds to a single gene with a placement resolution of 1 Mb along the length of
the chromosome. The complete lists of genes and RH mapping data are presented in the supplement (Tables 1S–8S).
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called differentially expressed. To be included in our final
differentially regulated gene class, the given transcript was
required to be determined differentially regulated in the
same direction (up or down) at the statistically significant
levels (P<.05) in 12 independent comparisons (2 exper-
imental cell lines2 experimental conditions3 control cell
lines). Despite that an identified set of 165 upregulated
genes has been differentially expressed in described
experimental systems with an extremely high level of
confidence, we carried out Q-PCR confirmation analysis
for a subset of identified genes and confirmed their differ-
ential expression in all instances using an additional
independent normal human prostate epithelial cell line as
a control.
Quality Performance Criteria Adopted for the Affymetrix
GeneChip System and Applied in This Study
Forty to 50% of the surveyed genes were called present
by the Affymetrix software in these experiments. This is at
the high end of the required standard adopted in many
peer-reviewed publications using the same experimental
system. Transcripts that are called present by the Affyme-
trix software in any given experiment were determined to
have the signal intensities higher in the PM probe sets
Figure 3. (continued)
Figure 4. Cancer-associated transcriptomeres located on chromosome 11 correspond well to the region of increased gene expression identified on human
chromosome 11 [4]. The experimental protocols are described in the legends to Figures 1–3 and in the Materials and Methods section. The distribution of regions
of increased gene expression and gene density along human chromosome 11 are shown in the box and originally described in Ref. [4].
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compared to single-nucleotide MM probe sets and back-
ground at the statistically significant level. This analysis
was performed for each individual transcript using a unique
set of 20 PM probes vs 20 single nucleotide MM probes. In
our final list of 165 genes, all transcripts were called
present in at least one experimental setting.
The inclusion error associated with two mRNA samples
from identical cell lines was 2.7% for a difference called by
the Affymetrix software. Thus, two independently obtained
mRNA from the same cell lines will have 2.7% false pos-
itives. When a third independently derived epithelial cell line
was included, only 4 (0.06%) of 7129 genes were called
differentially expressed. The expression profiles of the NPE
cell lines used in our experiments were determined to be
indistinguishable. Therefore, controls are not likely sources
of errors in gene expression analysis performed in this study.
This is particularly important because the strategy adopted in
this study is based on the idea that expression differences
will not be called statistically significant by chance in the
same direction in multiple arrays and during multiple inde-
pendent comparisons of different phenotypes and variable
experimental conditions. To impose additional stringent
restrictions on the possibility of a gene to be detected as
concordantly differentially regulated by chance, we apply the
use of multiple experimental models and vastly variable
experimental settings such as in vitro and in vivo growth
and varying growth conditions. A similar strategy for the
identification of consistent gene expression changes based
on a concordant behavior of the differentially regulated
genes using the Affymetrix GeneChip system and software
was applied and validated in several peer-reviewed pub-
lished papers (e.g., see Refs. [17,18]). We applied more
stringent criteria in our study, requiring a concordance in at
least 12 of 12 experiments compared to six of six compar-
isons in Ref. [17] and four of six comparisons in Ref. [18].
Ishida et al. [18] provided a formal statistical justification that
four or more concordant calls out of six comparisons cannot
be explained by chance, with the probability in the range
of 104.
Calculation of a Clustering Effect
For every member of individual sets of genes with
increased mRNA abundance levels, we identified the pre-
cise chromosomal position by retrieving the RH mapping
data using the LocusLink database (http://www.ncbi.nlm.
nih.gov). Within each gene set for all combinations of the
three nearest neighbors distributed along the length of the
individual chromosomes, we calculated the average dis-
tance between three nearest neighboring genes (the exper-
imental clustering distance). A clustering effect analysis
was performed for each individual data set (set of tran-
scripts differentially regulated in the prostate cancer cell
lines as well as sets of transcripts identified in published
papers for corresponding type of human cancer, human
cell cycle, p53 response, and dsRNA response). As a first
step of this analysis, we identified a precise chromosomal
position (in Mb) for every gene listed in individual data
sets. We were able to calculate the average distance
between three nearest neighbors only for genes with
chromosomal position defined in Mb. Typically, the fraction
of genes with chromosomal positions defined with this
precision constitutes f65% to 80% of total genes included
in data sets based on a gene expression analysis. To
account for random pseudo-clustering effect, we performed
a similar analysis for a randomly selected set of 165 genes
from the list of 7129 transcripts comprising Affymetrix
Hu6800 probe set (the random gene set). To determine
the expected random density of gene distribution, we
calculated the average distance between three nearest
neighbors within a random gene set from a total of 102
individual measurements (the average random clustering
distance). The clustering effect in the experimental data set
was calculated as a ratio of the average random clustering
distance to the individual measurements of the experimen-
tal clustering distance within a given class of differentially
regulated transcripts. To account for the effect of random
chromosomal distribution of transcripts present on the
array, we generated two independent random lists of
genes derived from genes present on the array. We utilize
one random gene list as a control set to generate the
expected density of transcript distribution and a second
random gene list was used as mock experimental tran-
script set. The cutoff value for the identification of the
transcription activation clusters in the experimental data
sets was set to exceed the expected random density of
gene distribution by at least 10-fold. A higher ratio due to a
shorter experimental clustering distance was interpreted as
a more significant clustering effect. The random distribution
of the individual clustering distances was obtained by
performing a similar analysis for the second random gene
set (a total of 105 individual measurements). There were
no random pseudo-clusters exceeding the cutoff value that
was set for the identification of the transcription activation
clusters. The data were plotted for genome-wide visual-
ization of distribution of transcription activation clusters
(Figure 2 and Figures 1S–7S, Supplement).
Q-PCR Confirmation Analysis of the Differentially Regulated
Genes
To confirm the differential regulation of the transcripts
comprising a PC3/LNCaP consensus class using an inde-
pendent method, a sample of 14 genes (12 upregulated and
2 downregulated genes) was tested using Q-PCR (quantita-
tive polymerase chain reaction) on an ABI7900 according to
the vendor’s recommended protocols (http://www.applied-
biosystems.com/support/tutorials/). This PCR experiment
used a further new batch of RNA from a third normal human
prostate epithelial cell line and human transcript–specific
pairs of PCR primers. In addition, for seven genes (two
upregulated, three downregulated, and two controls), we
carried out a semiquantitative reverse transcription (RT)
PCR confirmation analysis (Figure 1 and data not shown).
For confirmation of array results, RNA expression levels
were quantified by semiquantitative PCR. An amount of 0.5
Ag of total RNA from NPE cells or prostate tumor cells was
reverse-transcribed into cDNA using Superscript II RNase
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H Reverse Transcriptase Kit (Invitrogen) according to the
manufacturer’s instructions. Semiquantitative PCR primer
sequences were selected for each cDNA with the aid of
commercial software: chromosome 18—oligo 3 (CYB5) for-
ward: 5V AAA TTA CAC ATT AAG GAA ACA TCA A 3V,
reverse: 5V GAA GAG CCT GCT TTG GAC AC 3V, product
size: 216 bp; oligo 4 (maspin) forward: 5V AGA CATT CTC
GCT TCC CT 3V, reverse: 5V AAT TTT GAC CCC TTA TGG
GC 3V, product size: 333 bp; oligo 5 (serpin B3) forward: 5V
CAG ATG TTC TGG TAA ACTGAT TGC 3V, reverse: 5V AAA
GAA ATG TGT GTT TCT AGG TTG C 3V, product size: 330
bp; oligo 8 (serpin B2) forward: 5V TGCTCT TCT GAA CAA
CTT CTG C 3V, reverse: 5V ATA GAA GGG CAT GGA GGG
AT 3V, product size: 339 bp; chromosome X—oligo 12 (mage
A12) forward: 5V GGT GGA AGT GGT CCG CAT CG 3V,
reverse: 5VGCCCTC CAC TGA TCT TTA GCA A 3V, product
size: 392 bp; oligo 13 (SYBL1) forward: 5V GCA ATC CAT
GTG ACT CAA G 3V, reverse: 5V GCA ATG AAT GGT TCA
ATC TG 3V, product size: 161 bp; oligo 14 (mage A3) forward:
5VTGAGTCTGAGCACGAGTTGC3V, reverse: 5VTTAAAA
GGA ACA TTT GAA CAA CTC C 3V, product size: 224 bp.
PCR reactions were performed with HotStarTaq DNA
Polymerase Kit (Qiagen, Valencia, CA) according to the
manufacturer’s instruction. An amount of 1 Al of RT product
was amplified by using 1.25 U of polymerase in a final
volume of 50 Al containing 1.5 mM MgCl2, 0.2 mM dNTP,
and 0.3 AM of each primer. The polymerase was activated
by incubation at 95jC for 15 minutes, and the reactions
were cycled 30 to 40 times at 95jC for 30 seconds, 56jC
for 30 seconds (chromosome 18) or 57jC for 30 seconds
(chromosome X), and 72 for 40 seconds, followed by a final
extension at 72jC for 7 minutes. PCR products at cycle 30,
35, or 40 were analyzed by electrophoresis through 2%
agarose gels containing ethidium bromide.
Results and Discussion
To define precise chromosomal positions of the genes over-
expressed in human prostate, breast, ovarian, and colon
cancers, we retrieved the radiation hybrid (RH) mapping data
of the individual genes using the LocusLink database (http://
www.ncbi.nlm.nih.gov). Our initial analysis was focused
on 165 genes overexpressed in vitro in two highly metas-
tatic human prostate carcinoma cell lines PC3MLN4 and
LNCaPLN3 compared to normal human prostate epithelial
cells (see Table 1S, Supplement for a complete gene list).
Genome-wide visualization of the chromosomal positions of
the 165 genes of PC3LN4/LNCaPLN3 consensus set
appears to indicate a clustering pattern of chromosomal
distribution of the UniGene and Gene Bank hits correspond-
ing to these genes (Figure 2a). To test this assumption, we
calculated a clustering effect within an experimental gene
set compared to a random gene set selected from the list of
genes subjected to a gene expression analysis. Interest-
ingly, we found that, in contrast to a random gene set, a
significant fraction (f40%) of the upregulated human pros-
tate cancer–associated genes appears to reside in small
continuous chromosomal regions comprising dense tran-
scriptional islands of at least three coregulated genes and
exceeding the expected random density of gene distribution
by at least 10-fold and often >100-fold (Figures 2, b–d and
Tables 1S and 9S, Supplement). We propose to call these
discrete continuous transcriptional islands of coregulated
genes the transcriptomeres. We performed clustering effect
analysis for genes upregulated in human tumors from
patients with breast [5], ovarian [6], colon [7], and prostate
[8] cancers and found that genes with increased transcript
abundance levels exhibited a similar clustering pattern of
chromosomal distribution (Figures 1S–3S, and Tables 2S–
4S, Supplement). Remarkably, when we compared the
results of an independent analysis of the chromosomal
distribution of the cancer-associated genes identified by
the global gene expression monitoring of the human pros-
tate cancer cell lines as well as clinical samples of breast
[5], ovarian [6], colon [7], and prostate [8] tumors, we found
that there are several shared chromosomal regions that
appear to be commonly targeted for transcriptional activa-
tion in different types of human cancer (Table 2). It should
be pointed out, however, that a majority of the cancer-
associated transcriptomeres appear to be nonoverlapping
and, thus, cancer type–specific (Figures 1S–3S and
Tables 1S–4S, Supplement).
Next we attempted to determine whether a gene expres-
sion profile characteristic of a physiological but highly rele-
vant to cancer process such as cell cycle would exhibit a
similar discrete nonrandom pattern of chromosomal distribu-
tion. Using the LocusLink database, we retrieved the RH
mapping data of the 378 genes comprising the human cell
cycle transcriptome [19]. We found that coordinate transcrip-
tional regulation of gene expression during human cell cycle
seems to occur in a nonrandom fashion from discrete con-
tinuous chromosomal regions, suggesting an epigenetic
regulatory nature of this phenomenon (Figures 4S and 5S
and Table 5S, Supplement). Furthermore, several of the
common MARTAs appear to be closely related to the human
cell cycle –associated transcriptomeres (Table 2 and
Figure 3, a and c; Tables 1S–5S, Supplement).
Lastly, we thought to analyze whether a transcriptional
response to the activation of certain signaling pathways, such
as double-stranded (ds) RNA-triggered signaling [20] or p53-
dependent transcription [21], would exhibit a nonrandom
pattern of chromosomal distribution. dsRNA is thought to be
the primary viral gene product that causes induction of type I
interferon synthesis and interferon production by virus-
infected cells. Activation of the interferon-inducible gene
cluster was consistently found in the clinical cancer samples
[5–7].We analyzed the RHmapping data for genes activated
in the type I interferon locus-deficient GRE cells in response
to the dsRNA treatment [20]. We found that dsRNA-induced
genes are distributed along human chromosomes in a non-
random fashion with the multiple clusters of transcriptionally
activated genes positioned at chromosomes 1, 2, 3, 4, 6, 7,
10, 12, 13, 14, 17, 19, and 20 (Figures 6S and Table 6S,
Supplement). Interestingly, one of the dsRNA response
clusters on chromosome 17 appears to be closely related to
the breast cancer–associated and cell cycle–associated
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transcriptomeres on chromosome 17 (Figure 3, a and b),
suggesting a potential overlap of corresponding transcription
activation pathways. Consistent with this hypothesis, several
others cancer type–specific transcriptomeres have overlap-
ping chromosomal positions with the dsRNA response clus-
ters (Figures 1S–6S and Tables 1S–6S, Supplement).
The p53-regulated genes [21] seem to exhibit a cluster-
ing pattern of chromosomal distribution represented by
multiple transcriptional islands at chromosomes 1, 6, 10,
12, 16, 17, 19, and 22 (Figures 7S and Table 7S, Supple-
ment). Two of the common cancer-associated transcripto-
meres (12q13, 52–63 Mbp; 17q21, 38–50 Mbp) appear to
overlap with the corresponding p53-regulated transcriptional
islands. Several others cancer type–specific transcripto-
meres demonstrated similar overlapping positional patterns
with the p53-regulated genes (Tables 1S–8S, Supplement),
suggesting a mechanism of consistent recurrent transcrip-
tional targeting in multiple human cancers of p53-regulated
chromosomal regions.
A recently generated human transcriptome map revealed
an apparent clustering of highly expressed genes in 12
normal and pathological tissue types to specific chromoso-
mal domains called regions of increased gene expression,
RIDGES [4]. As described here, clustering of cancer-asso-
ciated genes to the discrete regions of chromosomesmay be
related to the specific RIDGES, implying that selected chro-
mosomal domains of increased gene expression are prefer-
ential targets for transcriptional activation in human cancer
cells (Figure 4).
The stated goal of a systematic analysis of chromosomal
positions of cancer-associated genes was achieved by per-
forming such analysis for the transcripts that were previously
defined as being cancer-associated in published peer-
reviewed papers [5–8] as well as for a set of 165 upregulated
transcripts in xenograft-derived human prostate cancer cell
lines (this study). Our results imply that at least some of the
transcripts defined previously as tumor-associated may in
fact be the bystanders of the enhanced transcriptional read-
outs reflecting the increased proportion of cycling cells in
tumors and/or activation of the p53 response pathway. Our
analysis argues that without follow-up experiments, the dis-
tinction between so-called cancer-associated and prolifera-
tive transcripts is ambiguous at least for some genes
(particularly those that are located in the chromosomal
regions targeted for transcriptional activation during the cell
cycle) and may indeed reflect the relative enrichment of
clinical tumor samples with actively proliferating cells. Alter-
natively, these regions may have been targeted for recurrent
transcriptional activation because they harbor important cell
cycle control and/or survival genes.
We do not intend to imply that the chromosomal regions
are more important than the genes that may be associated
with malignancy. We believe that specific chromosomal
regions were targeted for transcriptional activation precisely
because they harbor the important genes. However, the
transcriptional readout from the particular chromosomal
region is, in our opinion, less reliable and is a more variable
endpoint that could be influenced by many variables such
as transcript stability, assay sensitivity, experimental con-
ditions, sample handlings, etc. Identification of different over-
expressed transcripts derived from the same chromosomal
region in multiple pathological and experimental conditions
may indicate that cells maintain the accessibility of the region
for direct transcriptional regulation, thus implying its potential
significance. Therefore, gene-specific induction can be
easily achieved when growth and/or survival requirements
are in place. Identification of common chromosomal regions
of transcriptional activation would facilitate a detailed and
precise gene-by-gene analysis of these regions by employ-
ing the most sophisticated state-of-the-art approaches such
as high-resolution array-based CGH, Q-PCR–based analy-
sis, promoter methylation survey, and direct sequencing.
Our data do not necessarily imply that the mechanism of
transcriptional activation within identified chromosomal
regions is exclusively epigenetic. In fact, some of these
regions are within the boundaries of well-established can-
cer-associated amplicons (e.g., 17q21 and 17q23 for breast
cancer), suggesting that at least in some cancer cell lines
and/or subset of tumors, activation of the transcription in
these regions could be associated with DNA amplification.
However, during the cell cycle progression of normal cells
and in response to the p53 overexpression, the mechanisms
of transcriptional activation are most likely epigenetic. One of
our main conclusions is that these regions are commonly
targeted for transcriptional activation under a wide range of
pathological and experimental conditions suggesting their
potential relevance. Most likely, transcription activation effect
can be achieved by engaging either epigenetic mechanisms
(normal cells and some cancer cells) or DNA amplification
(cancer cells).
In summary, accumulation of cancer-associated tran-
scripts in the mRNA abundance space seems to occur from
the discrete continuous chromosomal regions comprising a
set of transcriptional islands of coregulated physically adja-
cent genes (the transcriptomeres). Most of the cancer-
associated transcriptomeres appear to exhibit a cancer
type–specific pattern of chromosomal distribution. How-
ever, several of the MARTAs exhibited a recurrent over-
lapping pattern of chromosomal distribution in human
prostate, breast, ovarian, and colon cancers, suggesting a
mechanism of preferential targeting for transcriptional acti-
vation in multiple types of human cancer of the selected
chromosomal regions.
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